Du Wentao Of Humanwell Pharmaceutical: Innovation Drives Performance Acceleration And Sets Up A Model For International Development Of Pharmaceutical Enterprises

Starting from the unmet clinical needs, it is one of the path choices for pharmaceutical enterprises to break the situation by driving performance acceleration through R & D innovation.

On September 26, Du Wentao, vice president of humanwell Pharmaceutical Group and President of Yichang humanwell, pointed out at the 2020 (4th) China big health industry summit sponsored by 21st century economic report that "there are still many unknown human problems to be solved, including unknown epidemic diseases and unmet clinical needs. Pharmaceutical enterprises should launch better solutions as soon as possible from the perspective of R & D innovation. For example, investment in the research and development of innovative drugs was started in 2008, and this year it began to enter the harvest stage. The new drug rimazolom benzenesulfonate, a new class 1.1 narcotic drug, was approved to go on the market in July this year, breaking the situation that there was no innovative drug on the market in the field of anesthesia and sedation in the world for nearly 30 years. "

At present, humanwell is trying to establish an innovation driven internationalization development template of pharmaceutical enterprises through the construction of R & D system and the integration of international resources. Up to now, humanwell has 1678 R & D technicians, forming a research team with overseas pharmaceutical experts and domestic pharmaceutical doctors and masters as the core. At the same time, there are more than 200 products under development, including more than 20 class 1 new drugs. Some of them have progressed to the stage of production review and some products have entered the stage of clinical phase III.

Du Wentao. Information map

According to the public data, humanwell is one of the representative enterprises in China that have successfully cultivated the subdivided fields. Among its four core businesses, the market of narcotic and analgesic products ranks first in China, the market of fertility regulating drugs ranks second in China, the market of Uygur ethnic medicine ranks first in China, and the business of gender health ranks second in the world. Renfu has a good ability to export narcotic drugs to many countries and regions in the world.

"We will also continue to deepen the subdivision field, and continue to build product chain and product group through R & D innovation." According to Du Wentao, the company has built a core product line covering narcotic drugs, hormone products, natural drugs, sexual health, psychotropic drugs, skin drugs, etc., focusing on unmet clinical needs. The completion of these product pipelines depends on the R & D system established by humanwell. The company has built six technical platforms, including innovative small molecule drug technology platform, transdermal drug delivery technology platform, oral mucosal drug delivery technology platform, oral sustained-release technology platform, special drug anti-abuse technology platform, long-acting microspheres and liposome technology platform, and cooperates with Academician Shu Hongbing of Wuhan University, Chen Fener of Wuhan Engineering University and Tsinghua University The platform, the cooperation platform of West China Hospital of Sichuan University, and the platform of Institute of process engineering, Chinese Academy of Sciences, carried out industry university research cooperation, respectively, to carry out the screening and drug forming research of immunomodulatory drugs, the screening of new compounds and raw material technology innovation, and the screening of known target compounds, thus forming mechanism research, compound design, compound process optimization and preparation Research system.

Another strategic layout of humanwell pharmaceutical is internationalization. By focusing on R & D and aiming at foreign countries, we will strive to achieve the strategic layout of international and domestic dual circulation. At present, the company's overseas revenue accounts for about 20%, and domestic business accounts for about 80%. In 2019, the revenue of overseas medicine has reached 2.7 billion yuan.

"At present, the development strategy of humanwell medicine is to focus on the domestic big cycle, and take the road of international and domestic dual circulation." Du Wentao explained, "in the first ten years, we mainly took the road of generic drugs and imitation of highly difficult preparations. However, we will strive to integrate global R & D and global pharmaceutical R & D and global pharmaceutical innovation and marketing

The international layout of humanwell medicine can be traced back to 2010. It aims to integrate the global R & D resources, and integrate with the existing advantages of humanwell, cutting-edge directions and international project cooperation. Up to now, the company has set up 5 R & D centers in the world, including the group Central Research Institute in Wuhan, focusing on generic and innovative drugs with high access threshold. The company has more than 80 anda approval documents and more than 100 overseas research projects. In 2018, the company obtained 13 anda approvals, ranking first in China, 4 in 2019 and 2 in the first half of 2020. The company has already held 8 anda controlled-release preparations.